

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Yang *et al.* Confirmation No.: 6917
Serial No.: 10/538,134 Filing Date: June 9, 2005
Patent No.: 7,271,172 B2 Issue Date: September 18, 2007
Title: PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5
ANTAGONISTS

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR §1.322

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge any fees or to credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,


Bonnie L. Deppenbrock
Attorney for Patentee
Registration No. 28,209

Date: October 5, 2007
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: (919) 483-1577
Facsimile: (919) 483-7988

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES
PATENT & TRADEMARK OFFICE ON October 5, 2007.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,271,172 B2

Page 1 of 1

APPLICATION NO. : 10/538,134


ISSUE DATE : September 18, 2007

INVENTOR(S) : Yang *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

The chemical structure of Claim 3 (Column 115, Lines 10-15) should read as follows:



Claim 3 (Column 115, Line 40) should read as follows:

- each R^p is independently selected from the group consisting of halogen, $-CF_3$, --

Claim 3 (Column 115, Line 61) should read as follows:

- each R^7 is independently selected from the group consisting of halogen, $-CF_3$, --

Claim 3 (Column 116, Lines 21-25) should read as follows:

- each R^q is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclylalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, and hetero-

Claim 5 (Column 116, Lines 46-47) should read as follows:

- 5. The compound of claim 3 wherein R^1 is phenyl mono- or di-substituted with halogen. --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GLAXOSMITHKLINE

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2